BioSpace News Archive

First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced it has been recognized by Frost & Sullivan for best practices in Technology Innovation in the Rapid Diagnostics Industry.

Since 2015, hard-working Canadians have proven what has long been understood: a strong economy starts with a strong middle class.

BOC Sciences, a business of BOCSCI Inc., has announced to launch its chiral solution service in this late March, in an active response to the increasing demands of its global clients for chirally pure APIs

Shuwen Biotech announces that Tasly Pharmaceutical Group has tapped Shuwen Biotech for clinical services and proprietary diagnostics for its oncology drug candidates.

Santhera Pharmaceuticals (SIX: SANN) announces its intention to file an application for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) for the treatment of respiratory dysfunction in Duchenne muscular dystrophy (DMD) with the European Medicines Agency (EMA).

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, has announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts, as detailed in the press release

Pressure BioSciences, Inc. (OTCQB: PBIO ) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced the establishment of a Center of Excellence (“CoE”) at Dr. Christine Vogel’s laboratory at New York University (“NYU”)’s Center for Genomics and Systems Biology (the “GSB Center”).

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia.

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced Week 24 results of FINCH 1, an ongoing, randomized, double-blind, placebo- and active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis

AngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtrac Radiation Dose Monitoring System.